title: [Prognostic Significance of the Percentage of Blasts with CD34+/CD38low/-/CD123+Phenotype in Acute Myeloid Leukemias].
abstract: OBJECTIVE
  To investigate the percentage of blasts with the CD34+/CD38low/-/CD123+phenotype in de novo acute myeloid leukemia (AML) patients and analyse its correlation with prognosis.
  
  
  METHODS
  The percentage of CD34+/CD38low/-/CD123+cells in the blast population of 148 newly diagnosed patients with AML was determined by using flow cytometry and its correlation with complete response, disease-free survival and overall survival were evaluated.
  
  
  RESULTS
  The median percentage of CD34+/CD38low/-/CD123+cells in newly diagnosed patients was 2.8% (ranged from 0.01 to 67%). The high expression of CD34+/CD38low/-/CD123+in AML patients positively correlated with the NPM1 wild-type (χ2=5.194,P<0.05), but did not relate with the positive FLT3-ITD mutations (χ2=0.418,P>0.05). Further multivariable analysis showed that the higher expression of the CD34+/CD38low/-/CD123+was associated with lower complete remission (P<0.05), worse disease-free survival(P<0.01) and shorter overall survival(P<0.01) in AML patients.
  
  
  CONCLUSIONS
  The percentage of CD34+/CD38low/-/CD123+cells at diagnosis significantly correlates with the response to treatment and survival. This prognostic marker may be used to rapidly identify the risk of treatment failure in clinical practice.
authors.affiliation: Department of Hematology, The Central Hospital of Xuzhou, Xuzhou 221009, Jiangsu Province, China.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Xiang
authors.affiliation: Laboratory of Hematology, Third Hospital Affiliated to Suzhou University, The First People's Hospital of Changzhou, Changzhou 213003, Jiangsu Province, China.
authors.forename: Guo-Qiang
authors.initials: GQ
authors.lastname: Qiu
authors.affiliation: Department of Hematology, Third Hospital Affiliated to Suzhou University, The First People's Hospital of Changzhou, Changzhou 213003, Jiangsu Province, China.
authors.forename: Xiao-Bao
authors.initials: XB
authors.lastname: Xie
authors.affiliation: Jiangsu Institute of Hematology, The First Hospital Affiliated to Suzhou University, Suzhou 215006, Jiangsu Province, China.
authors.forename: Jian-Nong
authors.initials: JN
authors.lastname: Cen
authors.affiliation: Department of Hematology, Children's Hospital of Suzhou University, Suzhou 215006, Jiangsu Province, China.
authors.forename: Shao-Yan
authors.initials: SY
authors.lastname: Hu
authors.affiliation: Department of Hematology, Third Hospital Affiliated to Suzhou University, The First People's Hospital of Changzhou, Changzhou 213003, Jiangsu Province, China. E-mail: guweiying2001@163.com.
authors.forename: Wei-Ying
authors.initials: WY
authors.lastname: Gu
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000032:analysis; D018952:Antigens, CD34 / Q000032:analysis*; D006801:Humans; D053650:Interleukin-3 Receptor alpha Subunit / Q000032:analysis; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000473:pathology; D000090243:Nucleophosmin; D010641:Phenotype; D011379:Prognosis
chemical_list: D018952:Antigens, CD34; D053650:Interleukin-3 Receptor alpha Subunit; C000716967:NPM1 protein, human; D000090243:Nucleophosmin; D051997:ADP-ribosyl Cyclase 1